<DOC>
	<DOCNO>NCT02062983</DOCNO>
	<brief_summary>Early identification patient risk cardiotoxicity represent primary goal cardiologist oncologist From adjuvant trial echocardiography ideal evaluating Left Ventricular function though operator dependent . The use technique endomyocardial biopsy , troublesome clinical practice Cardiac magnetic resonance imaging ( MRI ) great reproducibility evaluate leave ventricular ejection fraction ( LVEF ) . This technique provide morphological , functional , perfusion , viability information one assessment . It expensive time consume id diagnostic method choice patient technically limited image ECG patient discordant information clinically significant prior test</brief_summary>
	<brief_title>Early Predictor Herceptin Cardio Toxicity Breast Cancer Patients</brief_title>
	<detailed_description>Current standard care patient adjuvant trastuzumab baseline ECHO follow : Patients one medication undergo regular monitoring heart function treatment follow : 1 . Baseline evaluation LVEF prior inhibitor therapy 2 . Serial assessment LVEF use modality . There clear international guideline frequency method LVEF assessment . Cardiac function usually measure use ( ECHO ) echo cardiography multiple-gated acquisition ( MUGA ) The patient assess technique treatment avoid stress myocardium use exercise ionotropic agent , measure LVEF prevent earlier evidence cardiotoxicity . Changes early atrial ( E/A ) fill ratio reflect ventricular compliance may predict diastolic dysfunction decline LVEF . Diastolic dysfunction seem predictive cardiac morbidity mortality . Trials adjuvant trastuzumab use rule stop cardiotoxic agent . They identify subset high risk patient one two follow three criterion : 1 . A decline 10 % absolute LVEF normal base line 50 % less 2. high cumulative dose Doxorubicin ( &gt; 450 mg/m2 ) / ; 3. abnormal baseline LVEF &lt; 50 % Patients stop take doxorubicin LVEF decline less likely develop congestive heart failure ( CHF ) . Echocardiography use regularly monitor LVEF widely available . The MUGA , addition expose patient ionize radiation operator-dependent training use automation may overcome variation .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cardiotoxicity</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Breast cancer case histopathology prove invasive carcinoma HER 2 expression detect immunochemical stain and/ FISH . Age 18 80 year old . Patient criterion eligible Neu adjuvant/ adjuvant /metastatic ( Trastuzumab ) Herceptin therapy . Normal blood count , liver function test kidney function . Abnormal cardio vascular disease ( ex . Heart Failure , Ischemic Heart Disease , post CABG ) EFâ‰¤50 . Valvular abnormality reduce ejection fraction ( EF ) . Recent Myocardiac Infraction / Ischemia Pregnancy Breast feeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>